CorMedix director sells 40,000 shares at $11.88 per share

CorMedix Inc. director Steven Lefkowitz reported an open-market sale of common stock.

Rhea-AI Filing Summary

CorMedix Inc. director Steven Lefkowitz reported an open-market sale of common stock. On 12/09/2025, he sold 40,000 shares of CorMedix common stock at a weighted average price of $11.88 per share, with individual trades executed between $11.87 and $11.92. After this transaction, he directly owned 80,498 shares of CorMedix common stock.

In addition to his direct holdings, Lefkowitz is reported to beneficially own 30,152 shares through the Wade Capital Corporation Money Purchase Plan, for which he has voting and investment control, and 2,000 shares held by his wife. The filing reflects a routine insider ownership update rather than a company-level financing or operational event.

Insider Trade Summary

Net Seller: 40,000 shares

Net Sell 3 txns

Insider Lefkowitz Steven W

Role Director

Sold 40,000 shs ($475K)

Type	Security	Shares	Price	Value
Sale	Common Stock	40,000	$11.88	$475K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 80,498 shares (Direct); Common Stock — 30,152 shares (Indirect, Wade Capital Corporation Money Purchase Plan); Common Stock — 2,000 shares (Indirect, Reporting Person's Wife)

Footnotes (2)

1. F1. This transaction was executed in multiple trades at prices ranging from $11.87 to $11.92, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
2. F2. The Reporting Person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which the Reporting Person has voting and investment control).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CorMedix (CRMD) report in this Form 4?

The filing reports that director Steven Lefkowitz sold 40,000 shares of CorMedix Inc. common stock in an open-market transaction on 12/09/2025.

At what price did the CorMedix (CRMD) director sell his shares?

The shares were sold at prices ranging from $11.87 to $11.92 per share, with a weighted average price of $11.88 per share reported in the Form 4.

How many CorMedix (CRMD) shares does the director own after the transaction?

Following the reported sale, Steven Lefkowitz directly owned 80,498 shares of CorMedix common stock, as disclosed in the filing.

What indirect CorMedix (CRMD) holdings does the reporting person have?

The Form 4 states that Lefkowitz beneficially owns 30,152 shares through the Wade Capital Corporation Money Purchase Plan and 2,000 shares held by his wife.

What is the relationship of the reporting person to CorMedix (CRMD)?

The reporting person, Steven Lefkowitz, is identified as a director of CorMedix Inc. in the Form 4.

Does this CorMedix (CRMD) Form 4 involve any derivative securities?

The provided Table II section for derivative securities does not list any derivative transactions, so the reported activity relates to common stock only.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/10/2025 - 09:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lefkowitz Steven W

(Last) (First) (Middle)

C/O CORMEDIX INC.,

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		S		40,000	D	$11.88(1)	80,498	D
Common Stock								30,152	I(2)	Wade Capital Corporation Money Purchase Plan
Common Stock								2,000	I	Reporting Person's Wife

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $11.87 to $11.92, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

2. The Reporting Person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which the Reporting Person has voting and investment control).

	/s/ Steven Lefkowitz	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.